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Abstract
Background. Kidney stone formation is a major socioeco-
nomic problem in humans, involving pain, recurrent treat-
ment and renal insufficiency. As most renal precipitates
contain calcium as a major component, hypercalciuria is
the main risk factor for renal stone formation. Different
forms of hypercalciuria can be classified, which primar-
ily arise from defects in the main organs involved in cal-
cium homeostasis. A distinction can be made between re-
nal, absorptive and resorptive hypercalciuria, originating
from disturbed calcium handling in kidney, intestine and
bone, respectively. A positive family history predisposes
individuals to an increased risk of stone formation, which
strongly indicates the involvement of genetic susceptibility
factors. TRPV5 is the renal epithelial calcium channel that
is the gatekeeper protein in active calcium reabsorption in
the kidney. TRPV5 gene ablation in mice leads to severe
hypercalciuria, implying that TRPV5 is an interesting can-
didate gene for renal hypercalciuria in humans. This study
aims to identify and functionally characterize TRPV5 gene
aberrations in patients with renal hypercalciuria.
Methods. The TRPV5 coding region and intron–exon
boundaries were screened for gene mutations in 20 subjects
displaying renal hypercalciuria after which identified non-
synonymous polymorphisms were functionally character-
ized by patch-clamp analysis. Wild-type and TRPV5 chan-
nels including polymorphisms were transiently expressed in
human embryonic kidney (HEK) 293 cells and functionally
characterized by path-clamp analysis.
Results. Genotyping TRPV5 in renal hypercalciuria pa-
tients revealed three non-synonymous and five synonymous
polymorphisms. Electrophysiological characterization of
the TRPV5 mutants did not reveal significant functional
changes compared to wild-type TRPV5 channel record-
ings.
Conclusions. In this specific patient cohort, our data do not
support a primary role for TRPV5 in the pathogenesis of
renal hypercalciuria. However, TRPV5 cannot be excluded
as a candidate gene in hypercalciuria.
Keywords: calcium; hypercalciuria; ion channel; polymorphism;
TRPV5
Introduction
Hypercalciuria is the main risk factor in renal calcium stone
formation and constitutes universally an immense health
and socioeconomic problem [1,2]. In the United States,
∼5% of women and 12% of males develop a clinical episode
of kidney stone disease during their lifetime [3], accompa-
nied by severe pain and recurrent treatment. Approximately
80% of the renal stones contain calcium [4]. Besides hyper-
calciuria, other risk factors are low urinary volume, dietary
components, gender and previous development of calcium
stones [5,6]. Moreover, individuals with a positive family
history of nephrolithiasis have an enhanced risk of experi-
encing kidney stones in their lifetime compared to those
without a positive history [7]. This strongly implicates
gentetic factors as being involved in the pathogenesis of
hypercalciuria-related renal stone formation.
The identification of a causal factor and the establish-
ment of a categorization system for hypercalciuria remain
difficult. Currently, a tripartite classification is being used,
distinguishing renal, absorptive and resorptive hypercalci-
uria, of which the first two forms are the most common ones
[8]. In the body, the concerted action of kidney, intestine
and bone maintains a normal calcium balance. These organs
constitute the sites where the above-mentioned forms of
hypercalciuria primarily originate. As many transport pro-
teins and hormones are involved in the maintenance of the
calcium balance, defects in calcium homeostasis may have
many causal factors. Therefore, hypercalciuria is a complex
trait that can be polygenic and multifactorial in its aetiology.
In the past, several candidate genes were identified and as-
sociated with hypercalciuria [9,10]. Others were unsuccess-
ful in identifying loci or genetic variants linked to hyper-
calciuria, probably due to its heterogeneousity [9,11–13].
Thus, the nature of the genetic defects involved in most
cases of familiar hypercalciuria remains fairly unknown.
Transient receptor potential vanilloid member 5
(TRPV5) constitutes the rate-limiting calcium entry path-
way in renal transcellular calcium transport. The gene en-
coding the human TRPV5 channel is mapped to chromo-
some 7q35 and consists of 15 exons [14]. TRPV5 encodes
a protein of 729 amino acids [14,15]. Interestingly, TRPV5
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Table 1. Human TRPV5 primer sequences
Exon Forward primer Reverse primer
1 5′-TGCATACACAAGTCATACAGG-3′ 5′-AGGTGGGTCAGAGGGTCTGAGG-3′
2–3 5′-TCATTCTGCTATGACTGTCTCTTCC-3′ 5′-ACACCCTCCATCTCAAAGTTTCC-3′
4–5 5′-ATCAGGAACCTCCTGAGAGGGATGG-3′ 5′-ATGGGCCTCTGGCTTAATTAAGCC-3′
6–7 5′-TCAGCCTAGAACTGAGATATGGGG-3′ 5′-ACCTCTATTTCTCCCAGGGCCAGC-3′
8 5′-TAGATGCAGAGGTTTGCTGGTTCC-3′ 5′-AGGCCTGATCCTCCTTGGCATCC-3′
9 5′-ACTGATGAGCTGAGTGAGTGATGG-3′ 5′-TCCCTGAGTAGCATGGCTTCG-3′
10–11 5′-ACCCACAATGGCAAGTACAATGG-3′ 5′-AAGTCCTTGGAGTGAGAGTGACC-3′
12–13 5′-TACCACCCTGGTCACCACTATGC-3′ 5′-AAGAATGAGAGTGAACTTTCTGG-3′
14 5′-AGAATAAGTGCTAACCATGTCC-3′ 5′-ATGATCCACCATAACATTTTCC-3′
15 5′-TGAGTGAAGCTGGTTGCATGGTGC-3′ 5′-AGACAGGCTAATGCAGGCTCCAGG-3′
Oligonucleotide primers were developed for the amplification of each single exon of TRPV5, based on the genomic sequences. All primer sequences
were located in non-coding regions to analyse intron–exon boundaries as well.
gene ablation in mice evokes a robust renal calcium leak, re-
sulting in severe hypercalciuria. Besides hypercalciuria, the
TRPV5 knockout mice demonstrate bone degradation, de-
creased bone mineral density, hypervitaminosis D, calcium
hyperabsorption, normocalcaemia, polyuria and increased
urinary acidification [16,17]. Regarding the crucial impor-
tance of TRPV5 in body calcium homeostasis and further-
more the renal calcium wasting observed in the knock-
out mice, TRPV5 is an important candidate gene for renal
hypercalciuria.
The aim of our study was to investigate TRPV5 as a can-
didate gene for renal hypercalciuria. To this end, 20 patients
were selected for hypercalciuria with concomitant polyuria
or a low urinary pH and included in this study. These
patients were screened for TRPV5 gene aberrations. The
TRPV5 coding sequence and all exon–intron boundaries
within the TRPV5 gene were analysed. Non-synonymous
polymorphisms detected in TRPV5 were functionally char-
acterized by patch-clamp analysis in human embryonic kid-
ney (HEK) 293 cells.
Subjects and methods
Patient selection
Among the patients with idiopathic hypercalciuria, calcium nephrolithia-
sis or low bone mineral density attending the Department of Physiology
of Georges Pompidou Hospital, Paris, France, a familial evaluation is
commonly proposed. In this retrospective study, we screened the families
in which at least two family members had idiopathic hypercalciuria and
selected patients on the basis of the rate of urinary calcium excretion,
the 24-h urine output volume and fasting urinary pH. A selection of 20
renal hypercalciuria patients was made. Patients with hypercalcaemia, hy-
perthyroidism or malignant neoplasm were not included. This study was
performed in agreement with the bio-ethic French law. Informed consent
was obtained from all patients participating in the study.
Clinical evaluation
Subjects were evaluated after 2 days on a calcium (400 mg/24 h) and
sodium (150 mmol/24 h) diet, preceded by a 2-week period without an-
tiacid, non-steroidal anti-inflammatory drugs, diuretic agents, glucocorti-
coids, calcium, phosphate or vitamin supplements. A 24-h urine sample
was collected during the last day of the diet to measure total calcium excre-
tion. A 1-h fasting urine sample was obtained in order to measure urinary
pH, calcium and creatinine concentrations. Fasting blood samples were ob-
tained and analysed for plasma total and serum ionized calcium, parathy-
roid hormone (PTH), 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D3
and creatinine levels.
Serum and urine biochemistry
Total urinary and plasma calcium concentrations were measured by atomic
absorption spectrometry (Perkin Elmer 3300, Norwalk, CT, USA). Serum
ionized calcium levels were determined by an ICA2 electrode (Copen-
hagen, Denmark). Sodium levels were assessed by flame spectrophotom-
etry (Instruments Laboratory, Lexington, MA, USA). Urinary and serum
phosphate levels were analysed with a colorimetric reaction on a Tech-
nicon RA-XT chemistry analyser (Bayer, Germany). Creatinine levels
were measured according to Jaffe´’s method (RA-XT). Intact (1–84) serum
PTH was determined by the Nichols Allegro PTH immunoradiometric
assay (Nichols Institute, San Juan Capistrano, CA, USA). Serum 25-
hydroxyvitamin D3 levels were obtained by a radioimmunoassay, whereas
1,25-dihydroxyvitamin D concentration measurements were performed
with a radioreceptor assay (Incstar, Stillwater, MN, USA). Urinary pH
values were determined with an electronic ion analyser.
Phenotype assignment
Hypercalciuria was defined as a 24-h urinary calcium excretion exceed-
ing 0.1 mmol/kg body weight on a non-restricted diet. Renal hypercalci-
uria was defined by a ratio of fasting urinary calcium/creatinine (fasting
UCa/UCr) > 0.37 [18].
DNA extraction
DNA sample collection and storage were carried out according to stan-
dard methods. In short, 10 ml of peripheral blood was collected into
EDTA-containing tubes at the time of initial diagnosis and centrifuged
for 10 min at 3000 g to separate buffy coats and plasma. Total genomic
DNA was isolated from the buffy coat using a QIAmp Blood Kit (Qiagen
S.A., Courtaboeuf, France) according to the blood and body fluid proto-
col recommended by the manufacturer. Extracted DNA was quantified by
spectrophotometrical absorbance measurements.
Genotyping
Oligonucleotide primers were developed for the amplification of each
single exon of TRPV5, based on the genomic sequence. All primer sets
obtained from Biolegio (Nijmegen, The Netherlands) that were used to am-
plify the genomic DNA of TRPV5 by polymerase chain reaction (PCR)
are depicted in Table 1. Because of short intron sequences between exons
2 and 3, 4 and 5, 6 and 7, 10 and 11 as well as 12 and 13 of TRPV5,
these exons were amplified and sequenced as single fragments. Primer
sequences were located in non-coding regions to analyse the intron–exon
boundaries as well. PCR product purifications of all exons were per-
formed with the GenEluteTM PCR Clean-up Kit (Sigma, St Louis, MO,
USA) or Qiaex R© II Gel extraction kit (Qiagen, Hilden, Germany). DNA
sequencing was carried out by standard procedures at the sequence facility
of the Radboud University Nijmegen Medical Centre. Subsequently, we
assessed the alignment and comparison of the patient sequences with
the human TRPV5 mRNA sequence, obtained from the NCBI nucleotide
database (NM_019841).
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DNA constructs
To investigate the channel function of the TRPV5-A8V, R154H and A561T
gene polymorphisms, the mutations were each prepared by in vitro mu-
tagenesis [Quickchange R© (Stratagene)] and cloned into the homologous
wild-type rabbit TRPV5 cDNA in the pCINeo/IRES-GFP vector [19,20].
The wild-type TRPV5 and TRPV5 mutant constructs were verified by
cDNA sequence analyses.
Electrophysiological analysis
The full-length cDNA encoding wild-type or mutated TRPV5 was trans-
fected into HEK293 cells, as described previously [19,20]. Patch-clamp
experiments were performed in the tight seal whole-cell configuration at
room temperature using an EPC-9 patch-clamp amplifier controlled by the
Pulse software (HEKA Elektronik, Lambrecht, Germany). Pipettes had re-
sistances between 2 and 5 m when filled with the recording solution.
Capacitance and series resistance were compensated. Access resistance
was monitored continuously using the automatic capacitance compensa-
tion of the Pulse software. Sodium currents were measured using a ramp
protocol. Cells were held at +20 mV and voltage ramps of 450-ms du-
ration each, ranging from −100 to +100 mV, were applied every 5 s.
Extracellular solution for sodium currents contained in mM 150 NaCl, 6
CsCl, 10 glucose and 10 HEPES/CsOH (pH 7.4). Calcium currents were
studied using a 3-s voltage step to −100 mV from a holding potential
of +70 mV. NaCl, 150 mM, was replaced with an equimolar amount of
N-methyl-D-glucamine-Cl (NMDG-Cl) from extracellular solution and 10
mM calcium was added to measure the calcium current. Current densities
were obtained by normalizing the current amplitude to the cell membrane
capacitance. Data were analysed using Igor pro software (Wavemetrics,
Lake, Oswege, NY, USA).
Statistical analyses
Electrophysiological data analysis was performed using IgorPro software
(Wavemetrics, Lake, Oswege, NY, USA). Data were depicted as means ±
SEMs. Significance was determined using Student’s t-test with P < 0.05
considered to be statistically significant.
Results
Patient selection and biochemical analyses
In order to investigate the involvement of TRPV5 gene aber-
rations in hypercalciuria, 20 subjects were included in this
study. All subjects demonstrated renal hypercalciuria (mean
fasting UCa/UCr 0.48 ± 0.02), with concomitant polyuria
or low urinary pH (Table 2). The mean urinary sodium ex-
cretion was 140 mmol/24 h (range: 40–300 mmol/24 h).
All patients showed normal serum PTH and calcium levels.
Mean 25-hydoxyvitamin D3 level was 42 ± 5 nM, whereas
the serum 1,25-dihydroxyvitamin D concentration was
110 ± 6 pM.
Sequence analysis in renal hypercalciuria patients
Polymorphisms identified in the coding sequence of
TRPV5 in renal hypercalciuria patients and expression
rates are listed in Table 3. The topology of the TRPV5
protein is depicted in Figure 1. Detected synonymous
polymorphisms were L205L, Y222Y, Y278Y, T281T
and T344T. The non-synonymous gene aberrations iden-
tified were A8V, R154H and A561T. Both the A8V
(dbSNP rs# cluster id: rs4252372) and R154H (rs4236480)
polymorphisms were previously identified and are listed
in single nucleotide polymorphism (SNPs) databases
(http://www.ncbi.nlm.nih.gov/SNP/). Allele frequency data
in the European control population showed 96% C- and
Table 2. Blood and urine biochemistry of included subjects
Blood Subjects Normal
Total calcium (mM) 2.26 ± 0.02 2.10–2.55
Ionized calcium (mM) 1.23 ± 0.01 1.15–1.32
Creatinine (µM) 75 ± 3 70–125
PTH (pg/ml) 38 ± 5 11–57
1,25(OH)2D (pM) 110 ± 6 45–110
25(OH)D3 (nM) 42 ± 5 20–100
Urine
Urinary calcium excretion
(mmol/24 h)
8.5 ± 0.4 <8.0
Urinary volume (l/24 h) 2.4 ± 0.1 1.0–1.5
Fasting UCa/UCr (mmol/
mmol)
0.48 ± 0.02 <0.4
Fasting urinary pH 6.0 ± 0.1 >5.0
Age (years) 44 ± 3
Weight (kg) 69 ± 3
A selection of 20 renal hypercalciuria patients was made. Renal hypercal-
ciuria was defined by a ratio of fasting urinary calcium/creatinine (fasting
UCa/UCr) > 0.37 mmol/mmol. Data are expressed as means ± SEMs.
Table 3. TRPV5 gene polymorphisms detected in renal hypercalciuria
patients
Exon Polymorphism Ht patients (%) Hm patients (%)
1 A8V 20 0
2
3
4 R154H 55 10
5
6 L205L 40 0
Y222Y 50 5
7 Y278Y 40 0
T281T 50 5
8 T344T 45 5
9
10
11
12
13 A561T 10 0
14
15
TRPV5 allele expression rates are depicted as percentage of patients
(n = 20) demonstrating the specific polymorphism in a heterozygous (Ht)
and homozygous (Hm) manner.
Fig. 1. Gene polymorphisms in the TRPV5 channel. The TRPV5 protein
topology is depicted in a putative 3-dimensional model, displaying six
transmembrane regions and intracellular N- and C-tails. Depicted in black
are the three TRPV5 non-synonymous polymorphisms demonstrated in
renal hypercalciuria patients, which were functionally characterized by
patch-clamp analysis.
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Fig. 2. Electrophysiological analysis of wild-type and mutant TRPV5 channels. Sodium (A and B) and calcium (C and D) currents in TRPV5 channels.
(A) Current–voltage relations for wild-type TRPV5 recorded in a divalent-free solution. (B) Histogram plotting the peak values at −80 mV for sodium
currents recorded from HEK293 cells transiently transfected with wild-type TRPV5 or mutant channels. (C) Calcium-induced inactivation of the
calcium current was measured with 10 mM extracellular calcium during a 3-s step to −100 mV from a holding potential of +70 mV in cells over
expressing wild-type TRPV5. (D) Histogram plotting the peak values for calcium currents at −100 mV recorded from HEK293 cells over expressing
wild-type TRPV5 or TRPV5 mutant channels. Current amplitudes were normalized to the amplitude of wild-type TRPV5.
4% T-allele frequencies for A8V, whereas R154H showed
38% A- and 62% G-allele frequencies (NCBI ss# assay id:
ss69030695). A561T frequencies were not determined in
the general population so far.
Effect of non-synonymous polymorphism on TRPV5
channel activity
The TRPV5 non-synonymous polymorphisms were char-
acterized by electrophysiological analysis. To this end,
each construct (wild-type TRPV5 and mutant TRPV5-
A8V, TRPV5-R154H and TRPV5-A561T) was transiently
transfected into human embryonic kidney (HEK293) cells
and the current characteristics were analysed by patch-
clamp measurements (Figure 2). HEK293 cells express-
ing wild-type TRPV5 displayed the typical inwardly rec-
tifying current–voltage relation in a divalent-free solution
(Figure 2A, 1137 ± 83 pA/pF at −80 mV, n = 14) and
a calcium-dependent inactivation of the calcium current
(Figure 2C, 938 ± 86 pA/pF at −100 mV, n= 13). As shown
in Figure 2B and D, the normalized amplitudes of both
sodium and calcium peak currents were not significantly
different between wild-type TRPV5 and mutant channels.
In order to investigate whether the calcium-dependent in-
activation pattern of TRPV5 was changed in the mutant
proteins, a 3-s voltage step to −100 mV from a holding
potential of +70 mV was applied to the cells. No signif-
icant difference was recorded between wild-type TRPV5
and mutant TRPV5 calcium-dependent inactivation.
Discussion
A positive family history forms a risk in the development of
hypercalciuria. Genes encoding calcium transport proteins
that are involved in the maintenance of the body calcium
balance are candidate genes in the pathogenesis of hypercal-
ciuria. Interestingly, mice genetically ablated for the renal
epithelial calcium channel TRPV5 demonstrate a severe
renal calcium leak. In the present study, TRPV5 gene aber-
rations were analysed and identified in 20 renal hypercalci-
uria patients with at least one affected relative. All subjects
displayed concomitant polyuria or decreased urinary pH,
which are symptoms presented by TRPV5 knockout mice
as well. Synonymous as well as non-synonymous polymor-
phisms were detected in the TRPV5 coding sequences of
renal hypercalciuria patients. Electrophysiological analysis
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of the TRPV5-A8V, R154H and A561T mutants compared
to wild-type TRPV5 did not show significant changes in
channel function. In this specific research population, our
data do not support a primary role for TRPV5 in the patho-
genesis of renal hypercalciuria. TRPV5 can, however, not
be excluded as a candidate gene in hypercalciuria.
An increased risk for the development of hypercalciuria
is present when a first-degree relative is diagnosed with
hypercalciuria [7]. This fact is a strong indication for the
existence of genetic susceptibility factors in the aetiology
of hypercalciuria. The epithelial calcium channel TRPV5,
which is a key player in renal active calcium reabsorption
was previously postulated to be an important candidate
gene in calcium metabolism-associated disorders [21].
Interestingly, characterization of the TRPV5 knockout
mouse model revealed that a functional defect of this
channel causes a severe renal calcium leak [16,22]. Muller
et al. previously screened for TRPV5 gene mutations
in nine families known to have autosomal-dominant
hypercalciuria [23]. No TRPV5 mutations were demon-
strated. In the present study, 20 subjects were selected for
renal hypercalciuria and concomitant polyuria or increased
urinary acidification in order to obtain a homogeneous
patient cohort. Although matched for symptoms presented
by the TRPV5 knockout animal model, no disease-causing
TRPV5 gene aberrations were detected, as revealed from
functional, electrophysiological analyses [23].
Non-synonymous gene polymorphisms lead to amino
acid changes that can alter the function of a protein. There-
fore, we determined the electrophysiological properties
of mutated TRPV5 channels containing non-synonymous
polymorphisms detected in the renal hypercalciuria pa-
tients. Patch-clamp analysis showed no significant changes
in sodium and calcium peak currents or calcium-dependent
inactivation curves in mutant TRPV5 proteins compared
to wild-type TRPV5. This finding suggests that the in-
dividual A8V, R154H and A561T polymorphisms do not
play a key role in the aetiology of hypercalciuria in this
studied patient cohort. TRPV5 cannot be excluded though,
as a candidate gene for renal hypercalciuria. The hetero-
geneity of hypercalciuria and the potential contribution of
several calcium transport systems in this complex trait are
enormous. Therefore, gene association studies should be
preferentially initiated in large, well-characterized patient
groups. In this perspective, specific haplotypes of several
polymorphisms together could cause an increased suscepti-
bility to hypercalciuria. Previously, unusual SNPs patterns
and haplotype differences were identified in the intestinal
calcium channel TRPV6, a homologue of TRPV5 involved
in the absorption of calcium in the intestine, among world-
wide populations [24]. Akey et al. suggested that a specific
TRPV6 haplotype comprising three non-synonymous SNPs
(C157R, M378V and M681T) resulted in a selective advan-
tage during human history. This might indicate a different
TRPV6 channel function related to specific haplotypes. A
recent study, investigating the functional characterization
of these TRPV6 variants by patch-clamp analysis, revealed
no significant differences in biophysical channel function,
although calcium-dependent inactivation might be affected
in the presence of specific TRPV6 haplotypes [25]. Un-
fortunately, the polygenic nature and the uncertainties of an
exact diagnosis for hypercalciuria hamper population-based
association studies for genetic hypercalciuria. In addition,
linkage analysis is a powerful method to identify genes in-
volved in familial hypercalciuria. Previously, Reed et al.
performed a genome-wide search in three families with ab-
sorptive hypercalciuria. A high maximum logarithm of the
odds score >12 was found for the region 1q23.4 to 24 in
which a hypothetical human orthologue of the rat soluble
adenylate cyclase was identified [26,27]. So far, a causative
relationship between soluble adenylate cyclase and hyper-
calciuria has not been identified. The latter investigations
underline the importance of further efforts to study mono-
genic causes of hypercalciuria.
In summary, TRPV5 gene polymorphisms were identi-
fied in renal hypercalciuria patients that were well charac-
terized and selected for concomitant polyuria or decreased
urinary pH, symptoms presented by the TRPV5 knock-
out mouse model. Electrophysiological analyses of a non-
synonymous TRPV5 gene aberration did not implicate the
A561T polymorphism in the aetiology of renal hypercal-
ciuria. TRPV5 cannot be excluded as a candidate gene for
hypercalciuria, as TRPV5 gene variants might be involved
in other hypercalciuric patient cohorts. Due to the hetero-
geneity of hypercalciuria and the possible involvement of
multiple calcium transport systems in this complex trait,
gene association studies should be performed in large, well-
characterized patient groups displaying hypercalciuria.
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